Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 254 of 254 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/28/07
End: 06/30/10
Due: 06/30/11
Phase: N/A
Priority: Normal
Start: 10/02/24
End: 02/03/27
Due: 02/03/28
Phase: N/A
Priority: Normal
Start: 06/06/17
End: 09/07/17
Due: 09/07/18
Phase: N/A
Priority: Normal
Start: 10/28/20
End: 10/02/21
Due: 10/02/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Expanded Access Program for Maraviroc At Multiple Centers | NCT00426660 | ViiV Healthcare | user2@example.com | None | 2007-02-28 | 2010-06-30 | 2011-06-30 | - | - | 2025-07-14 |
| A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV | NCT06652958 | ViiV Healthcare | user2@example.com | None | 2024-10-02 | 2027-02-03 | 2028-02-03 | - | - | 2025-07-14 |
| Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects | NCT03149848 | ViiV Healthcare | user2@example.com | None | 2017-06-06 | 2017-09-07 | 2018-09-07 | - | - | 2025-07-14 |
| Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) | NCT04630002 | ViiV Healthcare | user2@example.com | None | 2020-10-28 | 2021-10-02 | 2022-10-02 | - | - | 2025-07-14 |